<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120076</url>
  </required_header>
  <id_info>
    <org_study_id>DEXA and PAO</org_study_id>
    <nct_id>NCT05120076</nct_id>
  </id_info>
  <brief_title>Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy</brief_title>
  <official_title>Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy- a Double-blinded Placebo Controlled RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balgrist University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of Dexamethasone on postoperative pain and&#xD;
      nausea after periacetabular osteotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bernese periacetabular osteotomy (PAO) is a standard procedure with good mid and long-term&#xD;
      results. Postoperative pain is a great concern and postoperative pain management of great&#xD;
      importance. High demand for opiates and the associated side effects especially nausea limit&#xD;
      the postoperative rehabilitation.&#xD;
&#xD;
      Promising results to reduce postoperative pain and nausea have been achieved by perioperative&#xD;
      dexamethasone, which has a strong anti-inflammatory effect reducing pain and inflammation as&#xD;
      well as a strong anti-emetic effect, especially in total hip replacement.&#xD;
&#xD;
      It is our goal to compare the effect of perioperative intravenous dexamethasone (3x 4mg Amp.&#xD;
      Fortecortin =12mg prior to surgery and 3x4mg Amp. Fortecortin = 12mg at 8.00am of the first&#xD;
      postoperative day) to a control group (placebo) (3ml saline solution postoperative day 1 at&#xD;
      8.00am) regarding pain level, opiate consumption, postoperative nausea and patient&#xD;
      satisfaction.&#xD;
&#xD;
      A double-blinded prospective randomized control trial including up to 60 patients receiving&#xD;
      elective unilateral PAO will be conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Only the investigators as well as the head of anasthesiology will be informed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain level</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (worst possible pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain level</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (worst possible pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of opiates (morphinequivalent) consumed</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The authors will assess the amount of Opiates the Patient needed due to the performed Surgery during the hospital stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of anti-emetics consumed (Ondansetron)</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The authors will assess the amount of mg of anti- emetic drugs (Ondansetron) the Patient required during the Hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R). (0% worst, 100% best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).(0% worst, 100% best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).(0% worst, 100% best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vomiting events</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The authors will count the number of vomiting events postoperatively as a direct marker for postoperative Nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical therapy milestones 1</measure>
    <time_frame>1 week postoperatively</time_frame>
    <description>First steps in the hallway</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical therapy milestones 2</measure>
    <time_frame>1 week postoperatively</time_frame>
    <description>Walk up stairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical therapy milestones 3</measure>
    <time_frame>1 week postoperatively</time_frame>
    <description>Bicycle ergometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>2 weeks</time_frame>
    <description>The length of hospitalization will be obtained from the Patient Chart.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <condition>Postoperative Nausea</condition>
  <condition>Amount of Postoperative Opioid Use in Milligrams</condition>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 Mg/mL Injectable Solution</intervention_name>
    <description>s. arm/group description</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <other_name>Fortecortin Inject (Merck (Switzerland))</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>s. arm/group description</description>
    <arm_group_label>Placebo/ Control group</arm_group_label>
    <other_name>NaCL Braun (B Braun medical)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  General anasthesia&#xD;
&#xD;
          -  Elective periacetabular osteotomy for any reason&#xD;
&#xD;
          -  Written informed consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
          -  Competent German language skills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic pain patient, chronic lower back pain&#xD;
&#xD;
          -  Steroid or immunosuppressive drugs used within 6 months of surgery&#xD;
&#xD;
          -  Renal failure, hepatic failure&#xD;
&#xD;
          -  Relevant allergies&#xD;
&#xD;
          -  Pregnancy/ Breast feeding&#xD;
&#xD;
          -  Contraindications for Fortecortin treatment according to Swissmedic&#xD;
&#xD;
          -  Previous enrollment into the current study&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse Illness according to&#xD;
             &quot;Warnings and Precautions of Dexamethasone and NaCl&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zingg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominik Kaiser, MD</last_name>
    <phone>+41443865764</phone>
    <email>dominik.kaiser@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Catanzaro, study nurse</last_name>
    <phone>+41443867370</phone>
    <email>sabrina.catanzaro@balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik Balgrist</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Kaiser</last_name>
      <phone>+41443865764</phone>
      <email>dominik.kaiser@balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Patrickt Zingg</last_name>
      <email>patrick.zingg@balgrist.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No If requested the individual participant data will be made available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

